Application
Western blot analysis of extracts from HepG2 cells treated with EGF 200ng/ml 30', using IRF-3 (Phospho-Ser386) Antibody. The lane on the right is treated with the synthesized peptide.| Product Name | IRF3 (phospho Ser386) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit polyclonal antibody to IRF-3 (phospho Ser386)Mediates interferon-stimulated response element (ISRE) promoter activation. Functions as a molecular switch for antiviral activity. DsRNA generated during the course of an viral infection leads to IRF3 phosphorylation on the C-terminal serine/threonine cluster. This induces a conformational change, leading to its dimerization, nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of genes under the control of ISRE. The complex binds to the IE and PRDIII regions on the IFN-alpha and IFN-beta promoters respectively. IRF-3 does not have any transcription activation domains. |
| Immunogen | The antiserum was produced against synthesized peptide derived from human IRF-3 around the phosphorylation site of Ser386. |
| Modification | p-Ser386 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | ELISAWB |
| *Optimal dilutions/concentrations should be determined by the researcher.
: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Synonyms | IRF3 Interferon regulatory factor3 Interferon regulatory factor 3 IRF-3 (phospho S386) IRF-3 (phospho Ser386) IRF-3 (pS386) IRF-3 (pSer386) IRF-3 phospho S386 IRF-3 phospho Ser386 Phospho IRF-3 (S386) Phospho IRF-3 (Ser386) Phospho IRF-3 (pS386) |
|---|---|
| Target | IRF-3 |
| Molecular Weight(MW) | 47 kDa (note) |
| Tissue Specificity | IRF-3 (Phospho-Ser386) Antibody detects endogenous levels of IRF-3 only when phosphorylated at serine386. |
| Cellular Localization | Shuttles between cytoplasmic and nuclear compartments, with export being the prevailing effect. When activated, IRF3 interaction with CREBBP prevents its export to the cytoplasm. |
Application
Western blot analysis of extracts from HepG2 cells treated with EGF 200ng/ml 30', using IRF-3 (Phospho-Ser386) Antibody. The lane on the right is treated with the synthesized peptide.| Application Notes | *Optimal dilutions/concentrations should be determined by the researcher.
: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at -20 degrees Celcius. Product is stable for at least 1 year. |
| Storage Buffer | Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
